Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | TLR2 | O60603 | 3/20 | 0.46 |
| ▸ | PRKCA | P17252 | 1/20 | 0.45 |
| ▸ | PRKCE | Q02156 | 1/20 | 0.45 |
| ▸ | PRKCQ | Q04759 | 1/20 | 0.45 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.45 |
| ▸ | LPAR1 | Q92633 | 3/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.43 |
| ▸ | HTR2A | P28223 | 3/20 | 0.43 |
| ▸ | MGLL | Q99685 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4078613 | 0.91 | ALDH1A1 (0.44) | ALDH1A1LMNATLR2PRKCAPRKCE | |
| SCHEMBL13901272 | 0.90 | TLR2 (0.42) | ALDH1A1LMNATLR2PRKCAPRKCE | |
| SCHEMBL4255720 | 0.87 | ALDH1A1 (0.54) | ALDH1A1LMNATLR2PRKCAPRKCE | |
| SCHEMBL19300948 | 0.84 | ALDH1A1 (0.68) | ALDH1A1LMNATLR2PRKCAPRKCE | |
| SCHEMBL4301352 | 0.84 | LPAR1 (0.60) | ALDH1A1LMNATLR2PRKCAPRKCE | |
| SCHEMBL20793332 | 0.84 | ALDH1A1 (0.54) | ALDH1A1LMNATLR2PRKCAPRKCE | |
| SCHEMBL4078739 | 0.83 | MAPK1 (0.48) | ALDH1A1LMNATLR2PRKCAPRKCE | |
| SCHEMBL31752535 | 0.82 | HTT (0.51) | ALDH1A1LMNATLR2PRKCAPRKCE | |
| SCHEMBL10081340 | 0.82 | LTA4H (0.44) | ALDH1A1LMNATLR2LPAR1MGLL | |
| SCHEMBL13702235 | 0.81 | CYP2D6 (0.42) | ALDH1A1TLR2CYP2D6HTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090221684-A1 | Molecules for Gene Delivery and Gene Therapy, and Methods of Use Thereof | TRUSTEES OF BOSTON UNIVERSITY (US) | 2009-09-03 | — | — | US | disclosed |
| US-7507859-B2 | Functional synthetic molecules and macromolecules for gene delivery | FIFTH BASE LLC (US) | 2009-03-24 | — | — | US | disclosed |
| US-20060241071-A1 | Functional synthetic molecules and macromolecules for gene delivery | FIFTH BASE LLC | 2006-10-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060241071-A1 | Functional synthetic molecules and macromolecules for gene delivery | ANXA6, STING1, POLRMT | ALDH1A1 3722/4885LMNA 953/4885TLR2 2383/4885 |
| US-20090221684-A1 | Molecules for Gene Delivery and Gene Therapy, and Methods of Use Thereof | ANXA6, STING1, ADM2 | ALDH1A1 2863/4885LMNA 967/4885TLR2 2059/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.